The Pharmacokinetics/Pharmacodynamic Relationship of Durlobactam in Combination With Sulbactam in In Vitro and In Vivo Infection Model Systems Versus Acinetobacter baumannii-calcoaceticus Complex.

O'Donnell, John P; Bhavnani, Sujata M

O'Donnell, John P; Bhavnani, Sujata M.

Affiliation

O'Donnell JP; Department of Drug Metabolism and Pharmacokinetics, Entasis Therapeutics, Waltham, Massachusetts, USA.
Bhavnani SM; Institute for Clinical Pharmacodynamics, Schenectady, New York, USA.

Clin Infect Dis ; 76(Suppl 2): S202-S209, 2023 05 01.

Article in En | MEDLINE | ID: mdl-37125469

Subject(s)

Acinetobacter Infections; Acinetobacter baumannii; Humans; Sulbactam/pharmacology; Sulbactam/therapeutic use; beta-Lactamase Inhibitors/pharmacology; beta-Lactamase Inhibitors/therapeutic use; Anti-Bacterial Agents/pharmacology; Anti-Bacterial Agents/therapeutic use; Acinetobacter Infections/drug therapy; Acinetobacter Infections/microbiology; Monobactams/pharmacology; Monobactams/therapeutic use; beta-Lactamases; Microbial Sensitivity Tests

Key words

Acinetobacter; diazabicyclooctane; durlobactam; pharmacokinetics/pharmacodynamics; sulbactam

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Acinetobacter Infections / Acinetobacter baumannii Type of study: Risk_factors_studies Limits: Humans Language: En Journal: Clin Infect Dis Year: 2023 Document type: Article

Fulltext

XML

PubMed Links

Search on Google